Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

NeuroProtective role of HRI following cerebral ischemia

Description du projet

Une thérapie ciblée pour les accidents vasculaires cérébraux

Un accident vasculaire cérébral (AVC) se produit lorsqu’il y a un blocage de l’approvisionnement en sang d’une partie du cerveau. Il touche plus d’un million de personnes chaque année et les traitements d’urgence consistent généralement en la prise de médicaments pour dissoudre les caillots sanguins à l’origine de l’AVC. Les soins de l’AVC se concentrent ensuite sur la récupération d’un maximum de mouvements et de sensations grâce à la rééducation. Financé par le programme Actions Marie Skłodowska-Curie, le projet NeuProHRI vise à développer une nouvelle thérapie pour les AVC qui cible la cascade cellulaire de la kinase inhibitrice régulée par l’hème (HRI). Les chercheurs utiliseront différents modèles d’AVC pour étudier les voies activées par la kinase HRI et tester le résultat des composés sur le phénotype de l’accident vasculaire cérébral.

Objectif

Nowadays, cerebrovascular diseases are devastating conditions representing a large cause of mortality worldwide. It is estimated that 1.1 million people suffer a stroke every year in Europe. Due to the lack of a reliable treatment for stroke, it is important to keep looking for new treatments that stop the progression of the insult by providing neuroprotection, and even promote neuronal recovery for those neurons already affected by the condition. The goal of NeuProHRI is to study the potential of targeting the HRI kinase cellular cascade as a new therapeutic aim for stroke. To develop this, I will use a combination of cutting-edge molecular techniques to define the cellular pathways underlying the activation of the HRI kinase, and their effect on promoting neuroprotection in in vitro and in vivo models of stroke. First, I will decipher the molecular cascade following the activation of HRI in primary cultured neurons by pharmacological and genetic approaches. Then, in vitro models of stroke will be used to measure the impact of these treatments in cells with stroke-like phenotype. Finally, mouse models of stroke will allow me to tackle the impact of pharmaceutical and genetic treatments on in vivo brain tissue. Moreover, Ribo-seq analysis will be performed to study accurately protein synthesis and its relation to neuron-intrinsic pathways involved in stroke. There is a clear benefit of the mobility for both the applicant and the host, ensuring high quality results and dissemination. In this regard, the host will ensure the acquisition of new technical, management, tutorial and transferable skills. The applicant will also benefit from a multidisciplinary environment enhancing international collaboration that will surely contribute to diversify his career. Finally, via a specialized Career Development Plan, the host will provide the ideal training and validation environment, through which the applicant will reach unprecedented levels of professional maturity.

Champ scientifique

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.

Coordinateur

FUNDACION PUBLICA GALEGA INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Contribution nette de l'UE
€ 165 312,96
Adresse
TRAVESA DA CHOUPANA
15706 Santiago De Compostela
Espagne

Voir sur la carte

Région
Noroeste Galicia A Coruña
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée

Partenaires (1)